Piper Sandler keeps USD 14.00 target for Neogen stock

Published on 10/17/2026 at 22:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Adjusted EBITDA margin was 18.70 percent versus 17.00 percent in fiscal first quarter 2027. Neogen stock stood at EUR 10.52 on October 16, 2026.

Analyst target and operating margin

Piper Sandler set a USD 14.00 target for Neogen on October 7, 2026.
Adjusted EBITDA margin reached 18.70 percent versus 17.00 percent in fiscal first quarter 2027.
Neogen stock stood at EUR 10.52 at Lang & Schwarz on October 16, 2026 at 10:58 p.m. CEST.
The 52-week Nasdaq range was USD 5.37 to USD 14.26 as of October 16, 2026.

NEOG, US6404911066, Illustration mit AI erstellt.

Piper Sandler maintained a Buy rating and set a USD 14.00 price target for Neogen on October 7, 2026, putting the target 18.54 percent above the Nasdaq price of USD 11.81. The euro quotation stood at EUR 10.52 at Lang & Schwarz on October 16, 2026 at 10:58 p.m. CEST.

Margin improved in fiscal first quarter

Neogen's latest reported operating picture showed better adjusted profitability. According to Neogen on October 6, 2026, adjusted EBITDA reached USD 41.60 million in fiscal first quarter 2027, compared with USD 35.50 million in the prior-year quarter. Adjusted EBITDA margin rose to 18.70 percent from 17.00 percent, while GAAP revenue increased to USD 222.80 million from USD 209.20 million.

Price position and trading activity

The Nasdaq price of USD 11.81 on October 16, 2026 was 17.19 percent below the 52-week high of USD 14.26 and 119.74 percent above the 52-week low of USD 5.37. Trading volume was 2,458,666 shares, below the average volume of 3,251,873 shares.

The euro quotation was 1.22 percent below the EUR 10.65 Tradegate quote dated October 15, 2026. That comparison uses separate German-market observations, while the primary listing remains Nasdaq in USD.

Valuation and risk remain relevant

Neogen had a market capitalization of USD 2.6 billion as of October 16, 2026. The finance data also showed a negative trailing P/E of 46.64, reflecting the company's reported loss rather than a positive earnings multiple. Dividend yield was 0.00 percent.

MarketBeat also cited FDA-related HYCOAT risk as a potential legal, reputational and financial factor. That concern matters because the target rests on improving execution and margin expansion, not on current GAAP earnings.

Comparison with peers

Neogen (Nasdaq, USD): minus 1.22 percent, market capitalization USD 2.6 billion
IDEXX Laboratories (Nasdaq, USD): plus 2.41 percent, P/E 39.69, market capitalization USD 44.1 billion
Bio-Rad Laboratories (Nasdaq, USD): minus 3.05 percent, P/E 42.87, market capitalization USD 9.5 billion

What the target implies

Piper Sandler's USD 14.00 target is above the latest Nasdaq price, while the euro quotation remains below the October 15 Tradegate observation. The main operating evidence is the adjusted margin improvement reported for fiscal first quarter 2027.

Neogen stock stood at EUR 10.52 at Lang & Schwarz on October 16, 2026 at 10:58 p.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of Neogen stock.